Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fadel Partners Inc
LSE:FADL
|
US |
|
Kesselrun Resources Ltd
XTSX:KES
|
CA |
|
P
|
Prologis Property Mexico SA de CV
BMV:FIBRAPL14
|
MX |
|
E
|
Enish Inc
TSE:3667
|
JP |
|
Superkrane Mitra Utama Tbk PT
IDX:SKRN
|
ID |
|
D
|
Daiichi Commodities Co Ltd
TSE:8746
|
JP |
|
G
|
Genius Group Ltd
AMEX:GNS
|
SG |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (15.1), the stock would be worth $-10.98 (1 347% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.2 | $0.88 |
0%
|
| Industry Average | 15.1 | $-10.98 |
-1 347%
|
| Country Average | 16.7 | $-12.14 |
-1 480%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
9.7m USD | -1.2 | -0.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 22.4 | 88.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 726 | -1 708.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 23 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 28.1 | 27.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 11.3 | 17.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 15.9 | 34.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Brainstorm Cell Therapeutics Inc
Glance View
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
